发明名称 |
uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla |
摘要 |
The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis human patient, comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a method for providing neuroprotection to a human subject, the method comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof. |
申请公布号 |
BR112013014061(A2) |
申请公布日期 |
2016.09.13 |
申请号 |
BR20131114061 |
申请日期 |
2011.12.06 |
申请人 |
TEVA PHARMACEUTICAL INDUSTRIES LTD. |
发明人 |
DAN BAR-ZOHAR;DINA KOFLER;NORA TARCIC |
分类号 |
A61K31/47 |
主分类号 |
A61K31/47 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|